Koninklijke Philips N.V. $PHG Position Reduced by Earnest Partners LLC

Earnest Partners LLC trimmed its stake in shares of Koninklijke Philips N.V. (NYSE:PHG) by 1.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,480 shares of the technology company’s stock after selling 445 shares during the quarter. Earnest Partners LLC’s holdings in Koninklijke Philips were worth $774,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Choreo LLC boosted its stake in Koninklijke Philips by 4.6% during the 1st quarter. Choreo LLC now owns 14,530 shares of the technology company’s stock valued at $369,000 after acquiring an additional 633 shares during the last quarter. Allworth Financial LP boosted its stake in Koninklijke Philips by 16.2% during the 1st quarter. Allworth Financial LP now owns 4,638 shares of the technology company’s stock valued at $115,000 after acquiring an additional 645 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Koninklijke Philips by 16.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 5,221 shares of the technology company’s stock valued at $134,000 after acquiring an additional 732 shares during the last quarter. Assetmark Inc. boosted its stake in Koninklijke Philips by 1.7% during the 1st quarter. Assetmark Inc. now owns 59,806 shares of the technology company’s stock valued at $1,519,000 after acquiring an additional 982 shares during the last quarter. Finally, US Bancorp DE boosted its stake in Koninklijke Philips by 0.9% during the 1st quarter. US Bancorp DE now owns 109,831 shares of the technology company’s stock valued at $2,790,000 after acquiring an additional 1,014 shares during the last quarter. 13.67% of the stock is currently owned by institutional investors.

Koninklijke Philips Stock Performance

NYSE:PHG opened at $27.57 on Friday. Koninklijke Philips N.V. has a twelve month low of $21.48 and a twelve month high of $32.91. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average of $25.65 and a 200-day moving average of $25.03. The firm has a market cap of $26.54 billion, a price-to-earnings ratio of 145.09, a price-to-earnings-growth ratio of 0.75 and a beta of 0.75.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings data on Tuesday, July 29th. The technology company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.12. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $4.35 billion. Analysts forecast that Koninklijke Philips N.V. will post 1.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy”.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.